Literature DB >> 11053093

The final pathogenetic steps in focal bone erosions in rheumatoid arthritis.

S R Goldring1.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 11053093      PMCID： PMC1766621          DOI： 10.1136/ard.59.suppl_1.i72

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  45 in total

1.  TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.

Authors:  B R Wong; J Rho; J Arron; E Robinson; J Orlinick; M Chao; S Kalachikov; E Cayani; F S Bartlett; W N Frankel; S Y Lee; Y Choi
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

2.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.

Authors:  Y Y Kong; U Feige; I Sarosi; B Bolon; A Tafuri; S Morony; C Capparelli; J Li; R Elliott; S McCabe; T Wong; G Campagnuolo; E Moran; E R Bogoch; G Van; L T Nguyen; P S Ohashi; D L Lacey; E Fish; W J Boyle; J M Penninger
Journal:  Nature       Date:  1999-11-18       Impact factor: 49.962

4.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.

Authors:  H Yasuda; N Shima; N Nakagawa; S I Mochizuki; K Yano; N Fujise; Y Sato; M Goto; K Yamaguchi; M Kuriyama; T Kanno; A Murakami; E Tsuda; T Morinaga; K Higashio
Journal:  Endocrinology       Date:  1998-03       Impact factor: 4.736

5.  Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.

Authors:  H Takayanagi; H Iizuka; T Juji; T Nakagawa; A Yamamoto; T Miyazaki; Y Koshihara; H Oda; K Nakamura; S Tanaka
Journal:  Arthritis Rheum       Date:  2000-02

6.  Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.

Authors:  E M Gravallese; C Manning; A Tsay; A Naito; C Pan; E Amento; S R Goldring
Journal:  Arthritis Rheum       Date:  2000-02

7.  Parathyroid hormone-related peptide in synovial fluid and disease activity of rheumatoid arthritis.

Authors:  K Okano; T Tsukazaki; A Ohtsuru; H Namba; M Osaki; K Iwasaki; S Yamashita
Journal:  Br J Rheumatol       Date:  1996-11

8.  Synovium as a source of increased amino-terminal parathyroid hormone-related protein expression in rheumatoid arthritis. A possible role for locally produced parathyroid hormone-related protein in the pathogenesis of rheumatoid arthritis.

Authors:  J L Funk; L A Cordaro; H Wei; J B Benjamin; D E Yocum
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

9.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

10.  TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.

Authors:  B R Wong; R Josien; S Y Lee; B Sauter; H L Li; R M Steinman; Y Choi
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307
View more
  4 in total

1.  Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.

Authors:  Evan Romas; Natalie A Sims; Daphne K Hards; Mandy Lindsay; Julian W M Quinn; Peter F J Ryan; Colin R Dunstan; T John Martin; Matthew T Gillespie
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

2.  Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary Report.

Authors:  Maria Guadalupe Zavala-Cerna; Maria Cristina Moran-Moguel; Jesus Alejandro Cornejo-Toledo; Norma Guadalupe Gonzalez-Montoya; Jose Sanchez-Corona; Mario Salazar-Paramo; Arnulfo Hernan Nava-Zavala; Erika Anita Aguilar-Chavez; Miriam Fabiola Alcaraz-Lopez; Alicia Guadalupe Gonzalez-Sanchez; Laura Gonzalez-Lopez; Jorge Ivan Gamez-Nava
Journal:  J Immunol Res       Date:  2015-05-03       Impact factor: 4.818

3.  miR-145-5p Increases Osteoclast Numbers In Vitro and Aggravates Bone Erosion in Collagen-Induced Arthritis by Targeting Osteoprotegerin.

Authors:  Yaqing Chen; Xiaoxue Wang; Mengchen Yang; Wendong Ruan; Wei Wei; Dongmei Gu; Jing Wang; Xinling Guo; Lingxia Guo; Yuhua Yuan
Journal:  Med Sci Monit       Date:  2018-07-30

Review 4.  Bone phenotypes in rheumatology - there is more to bone than just bone.

Authors:  Christian S Thudium; Signe Holm Nielsen; Samra Sardar; Ali Mobasheri; Willem Evert van Spil; Rik Lories; Kim Henriksen; Anne-Christine Bay-Jensen; Morten A Karsdal
Journal:  BMC Musculoskelet Disord       Date:  2020-11-28       Impact factor: 2.362
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.